AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31517505 — intervention group
Group type: COMPARATOR
Intervention: Macrocirculatory perfusion parameters (systolic blood pressure)
Number of subjects: 66
Study 31517505 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (proportion of perfused capillaries) in normotensive patients
Number of subjects: 66
Study 31517505 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory perfusion parameters (perfused capillary density) in normotensive patients
Number of subjects: 66
Study 30570287 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 113
Study 30570287 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 113
Study 27183154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.08 mg/kg)
Number of subjects: 161
Study 27183154 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 161
Study 25622599 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 228
Study 25622599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 228
Study 25622599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228
Study 25622599 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 228
Study 25622599 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 228
Study 23694718 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel arm
Number of subjects: 895
Study 23694718 — intervention group
Group type: EXPERIMENTAL
Intervention: KELIM (CA-125 elimination rate)
Number of subjects: 895
Study 23694718 — intervention group
Group type: EXPERIMENTAL
Intervention: KPROD (CA-125 tumor production rate)
Number of subjects: 895
Study 23694718 — intervention group
Group type: EXPERIMENTAL
Intervention: K (tumor growth rate)
Number of subjects: 895
Study 21966787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal tablets (ketoconazole 800 mg + clindamycin 100 mg)
Number of subjects: 169
Study 21966787 — intervention group
Group type: COMPARATOR
Intervention: Vaginal capsules (ketoconazole 800 mg + clindamycin 100 mg)
Number of subjects: 169
Study 19933717 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc with zidovudine/lamivudine
Number of subjects: 759
Study 19933717 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz with zidovudine/lamivudine
Number of subjects: 759
Study 16401777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 228
Study 15528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouthrinse
Number of subjects: 24
Study 15528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse plus 100 mg/kg fluoride
Number of subjects: 24
Study 15528908 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 24
Study 11753327 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (toggle recoil)
Number of subjects: 105
Study 11753327 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 105
Study 9286238 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis and reinfusion of concentrated ascites (ARCA)
Number of subjects: 24
Study 9286238 — intervention group
Group type: COMPARATOR
Intervention: Total paracentesis plus intravenous albumin (PARA)
Number of subjects: 24
Study 8395725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin
Number of subjects: 0
Study 8395725 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 0
Study 3013571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin
Number of subjects: 20
Study 3013571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin with doxycycline
Number of subjects: 20
Study 3013571 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 20
Study 31563820 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-migraine questionnaire (PIN)
Number of subjects: 240
Study 31563820 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aura rating scale (VARS)
Number of subjects: 240
Study 29029571 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (II) training
Number of subjects: 52
Study 29029571 — intervention group
Group type: COMPARATOR
Intervention: Verbal rehearsal (VR) training
Number of subjects: 52
Study 26461252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about a distressing experience for 15 minutes on 3 consecutive days (Study 1)
Number of subjects: 0
Study 26461252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about a distressing experience for 15 minutes on 3 consecutive days (Study 2)
Number of subjects: 0
Study 26461252 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0
Study 26461252 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups (non-emotional topic writing or thinking)
Number of subjects: 0
Study 24190979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ra-223 plus best standard of care (BSoC)
Number of subjects: 0
Study 24190979 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best standard of care (BSoC)
Number of subjects: 0
Study 22649140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomized (AR) design
Number of subjects: 140
Study 22649140 — intervention group
Group type: COMPARATOR
Intervention: Multiarm balanced randomized (BR) design
Number of subjects: 140
Study 20189472 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide hydrochloride tablets
Number of subjects: 0
Study 18022695 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary N(2)O >= 27 microg/l
Number of subjects: 61
Study 18022695 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary N(2)O < 27 microg/l
Number of subjects: 61
Study 18022695 — intervention group
Group type: COMPARATOR
Intervention: Unexposed nurses
Number of subjects: 61
Study 18022695 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers with urinary N(2)O >= 27 microg/l
Number of subjects: 61
Study 15974489 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on Zusanli points with IV atropine premedication
Number of subjects: 15
Study 15974489 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture on Zusanli points without atropine
Number of subjects: 15
Study 15974489 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation on a non-acupoint
Number of subjects: 15
Study 12324914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 9
Study 12324914 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BHD)
Number of subjects: 9
Study 12324914 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 9
Study 10628604 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of pancuronium (n = 14)
Number of subjects: 30
Study 10628604 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of pancuronium (n = 16)
Number of subjects: 30
Study 10628604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 7862660 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in anti-HIV-1 antibody
Number of subjects: 86
Study 7862660 — intervention group
Group type: COMPARATOR
Intervention: Standard seronegative plasma
Number of subjects: 86
Study 2029920 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light phototherapy (Sylvania F20T12/G)
Number of subjects: 0
Study 2029920 — intervention group
Group type: COMPARATOR
Intervention: Blue light phototherapy (Philips TL/20W/52)
Number of subjects: 0
Study 6115104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 27
Study 6115104 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 27
Study 31151436 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT (haematopoietic stem cell transplant)
Number of subjects: 99
Study 31151436 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 99
Study 28415975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hula intervention for 6 months
Number of subjects: 250
Study 28415975 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 250
Study 26551773 — intervention group
Group type: EXPERIMENTAL
Intervention: 660-nm QS Nd:YAG laser
Number of subjects: 8
Study 26551773 — intervention group
Group type: COMPARATOR
Intervention: 532-nm QS Nd:YAG laser
Number of subjects: 8
Study 26158167 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic microwave ablation
Number of subjects: 47
Study 26158167 — intervention group
Group type: COMPARATOR
Intervention: Traditional opening group
Number of subjects: 47
Study 26158167 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic resection group
Number of subjects: 47
Study 23117205 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD‐VASH (intensive case management plus rent subsidy vouchers)
Number of subjects: 259
Study 23117205 — intervention group
Group type: COMPARATOR
Intervention: ICM alone
Number of subjects: 259
Study 19528841 — intervention group
Group type: EXPERIMENTAL
Intervention: sugar-free Red Bull energy drink (2 mg x kg(‐1) body mass caffeine or approximately 147 mg caffeine; 4 kcal/250 mL)
Number of subjects: 17
Study 19528841 — intervention group
Group type: COMPARATOR
Intervention: noncaffeinated, sugar-free placebo (lemon-lime flavored soft drink, tonic water, lime juice; 4 kcal/250 mL)
Number of subjects: 17
Study 17304888 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% hydrocortisone in moisturizing cream
Number of subjects: 0
Study 17304888 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream alone
Number of subjects: 0
Study 17304888 — intervention group
Group type: COMPARATOR
Intervention: No topical application
Number of subjects: 0
Study 15802775 — intervention group
Group type: EXPERIMENTAL
Intervention: Various agents for treatment and prevention of osteoporosis, specific agents not mentioned, duration not specified.
Number of subjects: 0
Study 12231498 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS‐1 (4 mm of interincisal opening)
Number of subjects: 23
Study 12231498 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS‐2 (14 mm of interincisal opening)
Number of subjects: 23
Study 10233200 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rizatriptan
Number of subjects: 24
Study 10233200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rizatriptan
Number of subjects: 24
Study 10233200 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan
Number of subjects: 24
Study 10233200 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg rizatriptan
Number of subjects: 24
Study 10233200 — intervention group
Group type: COMPARATOR
Intervention: 4 mg intravenous rizatriptan
Number of subjects: 24
Study 7745314 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged resection (group T)
Number of subjects: 121
Study 7745314 — intervention group
Group type: COMPARATOR
Intervention: Acute resection (group R)
Number of subjects: 121
Study 2383801 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight followed by 2.5 mg/kg body weight 2 and 0.5 hours before exercise)
Number of subjects: 7
Study 2383801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal feeding
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids infusion
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid infusion
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 10
Study 7054040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrients perfused into the distal small intestine
Number of subjects: 10
Study 31222893 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA 40%
Number of subjects: 20
Study 31222893 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study 29108091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose epinephrine (LDEPI) plus tranexamic acid (TXA)
Number of subjects: 195
Study 29108091 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diluted epinephrine plus tranexamic acid (TXA)
Number of subjects: 195
Study 29108091 — intervention group
Group type: COMPARATOR
Intervention: TXA alone (Control)
Number of subjects: 195
Study 26361642 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (n = 61)
Number of subjects: 121
Study 26361642 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 60)
Number of subjects: 121
Study 24417761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg · kg(‐1) loading dose over 10 min followed by 0.5 μg · kg(‐1) · h(‐1) infusion)
Number of subjects: 60
Study 24417761 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with no dexmedetomidine
Number of subjects: 60
Study 24417761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D and C)
Number of subjects: 60
Study 22650767 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS)
Number of subjects: 1600
Study 22650767 — intervention group
Group type: COMPARATOR
Intervention: Chart based algorithmic support system
Number of subjects: 1600
Study 20482477 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk training
Number of subjects: 36
Study 20482477 — intervention group
Group type: COMPARATOR
Intervention: Cycle training
Number of subjects: 36
Study 18773781 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial training group
Number of subjects: 24
Study 18773781 — intervention group
Group type: COMPARATOR
Intervention: Delayed training group
Number of subjects: 24
Study 18773781 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 24
Study 17060387 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+SB (stenting both the main vessel and the side branch)
Number of subjects: 413
Study 17060387 — intervention group
Group type: COMPARATOR
Intervention: MV (stenting the main vessel only, with optional stenting of the side branch)
Number of subjects: 413
Study 17060387 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+SB
Number of subjects: 413
Study 17060387 — intervention group
Group type: COMPARATOR
Intervention: MV
Number of subjects: 413
Study 12525719 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 1086
Study 12525719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1086
Study 12525719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 1086
Study 10782589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (ID) 0.15 mL
Number of subjects: 763
Study 10782589 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (IM) 1.0 mL
Number of subjects: 763
Study 8730607 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat products
Number of subjects: 80
Study 8730607 — intervention group
Group type: COMPARATOR
Intervention: Full-fat products
Number of subjects: 80
Study 1881719 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 34
Study 1881719 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 34
Study 6813899 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoctamide hydrogen succinate (BAHS) 600 mg
Number of subjects: 6
Study 6813899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (linoleic acid)
Number of subjects: 6
Study 29882110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental/incisive nerve block (MINB)
Number of subjects: 64
Study 29882110 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 64
Study 29071984 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 88
Study 29071984 — intervention group
Group type: COMPARATOR
Intervention: Sham‐Electroacupuncture (sham‐EA)
Number of subjects: 88
Study 25979975 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of pulse pressure (PP)
Number of subjects: 1099
Study 25979975 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of systolic blood pressure (SBP)
Number of subjects: 1099
Study 25979975 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of diastolic blood pressure (DBP)
Number of subjects: 1099
Study 25979975 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Number of subjects: 1099
Study 23417317 — intervention group
Group type: EXPERIMENTAL
Intervention: Argireline applied twice daily for 4 weeks
Number of subjects: 60
Study 23417317 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 60
Study 23417317 — intervention group
Group type: EXPERIMENTAL
Intervention: Argireline
Number of subjects: 60
Study 23417317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21484775 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 1252
Study 21484775 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1252
Study 19586727 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus contingency management (CM)
Number of subjects: 393
Study 19586727 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study 18200995 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt bronchial blocker (ABB) for right-sided surgery
Number of subjects: 40
Study 18200995 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen endotracheal tube (DLT) for right-sided surgery
Number of subjects: 40
Study 18200995 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt bronchial blocker (ABB) for left-sided surgery
Number of subjects: 40
Study 18200995 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen endotracheal tube (DLT) for left-sided surgery
Number of subjects: 40
Study 18200995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (ABB and DLT)
Number of subjects: 40
Study 14990522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy by general practitioners (5 to 7 sessions of 30 minutes each)
Number of subjects: 151
Study 14990522 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 151
Study 11548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg o.d.)
Number of subjects: 22
Study 11548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-50 mg b.i.d.)
Number of subjects: 22
Study 11548448 — intervention group
Group type: COMPARATOR
Intervention: Abrupt cessation of losartan and captopril
Number of subjects: 22
Study 11548448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10087430 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin managed by a nomogram
Number of subjects: 111
Study 10087430 — intervention group
Group type: COMPARATOR
Intervention: Standard warfarin management by attending physicians
Number of subjects: 111
Study 7921924 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus continuous oral chlorambucil (RT+CHL)
Number of subjects: 148
Study 7921924 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 148
Study 3139463 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH) (Metrodin, Serono Laboratories, Inc.)
Number of subjects: 98
Study 3139463 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG) (Pergonal, Serono)
Number of subjects: 98
Study 31226717 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided de-escalation of dual antiplatelet treatment (DAPT)
Number of subjects: 2610
Study 29112565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral antibiotics
Number of subjects: 190
Study 29112565 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation
Number of subjects: 190
Study 25803605 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Smart, Live Strong (ESLS) intervention
Number of subjects: 614
Study 23890993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge exercise with arm movement
Number of subjects: 20
Study 23890993 — intervention group
Group type: COMPARATOR
Intervention: Bridge exercise without arm movement
Number of subjects: 20
Study 23890993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging on the floor
Number of subjects: 20
Study 23890993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging on the ball
Number of subjects: 20
Study 23890993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging on the floor and on the ball
Number of subjects: 20
Study 21531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents followed by a 40-day prednisone treatment
Number of subjects: 375
Study 21531233 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 375
Study 21531233 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (controls)
Number of subjects: 375
Study 19290533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative extrapleural chest tube (EPCT) drainage, n = 21
Number of subjects: 50
Study 19290533 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative EPCT drainage, n = 29
Number of subjects: 50
Study 19290533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 16436648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (400 mg/day target dose)
Number of subjects: 208
Study 16436648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 15211369 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg orlistat per day (group 1; n=30)
Number of subjects: 57
Study 15211369 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg orlistat plus 1700 mg metformin per day (group 2; n=27)
Number of subjects: 57